AMPLIA THERAPEUTICS LTD (ATX) - Pioneering Cancer Treatment: CEO & MD, Dr. Chris Burns on FAK Inhibitors, Pancreatic Cancer Breakthroughs, and the ACCENT Trial's Promise

ASX BRIEFS

Send us a text

Get ready to explore the cutting-edge world of cancer treatment with Dr. Chris Burns, CEO & MD of Amplia Therapeutics Limited and co-recipient of the 2024 Prime Minister's Prize for Innovation. Our latest episode of ASX Briefs takes you inside Amplia's groundbreaking work with Focal Adhesion Kinase (FAK) inhibitors, specifically their promising small molecule inhibitor, designed to tackle pancreatic cancer head-on. Dr. Burns shares the significant milestones in their ACCENT trial, including the recruitment of the first 26 patients and the remarkable achievement of six confirmed partial responses, which may signal a new frontier in cancer therapy.
Join us as Dr. Burns uncovers the science behind Amplia's innovative approach and how their treatment aims to enhance the effectiveness of existing therapies. He discusses the trial's progress, the potential for improved patient outcomes, and the exciting path forward with further recruitment underway. This episode is a compelling listen for anyone passionate about the future of oncology and the relentless pursuit of breakthroughs in cancer treatment. Don't miss the chance to hear firsthand from a leader at the forefront of medical innovation.